Search

Your search keyword '"Gill, Beant"' showing total 50 results
Start Over Author "Gill, Beant"
50 results on '"Gill, Beant"'

28. Image-Guided Brachytherapy for Definitive Treatment of Inoperable Endometrial Carcinoma

Author

Gebhardt, Brian J., primary, Gill, Beant S., additional, Kim, Hayeon, additional, Houser, Christopher, additional, Glaser, Scott M., additional, Kelley, Joseph, additional, Sukumvanich, Paniti, additional, Edwards, Robert, additional, Comerci, John, additional, Olawaiye, Alexander, additional, Courtney-Brooks, Madeleine, additional, Boisen, Michelle, additional, Berger, Jessica, additional, and Beriwal, Sushil, additional

Published
2017
Full Text
View/download PDF

35. Erratum to ‘‘Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma’’ Brachytherapy 13 (2014) 542–547

Author

Gill, Beant S., primary, Kim, Hayeon, additional, Houser, Chris, additional, Olson, Adam C., additional, Kelley, Joseph, additional, Edwards, Robert P., additional, Comerci, John, additional, Sukumvanich, Paniti, additional, Olawaiye, Alexander B., additional, Huang, Marilyn, additional, Courtney-Brooks, Madeleine, additional, and Beriwal, Sushil, additional

Published
2015
Full Text
View/download PDF

42. Prostate SBRT

Author

Gill, Beant S., primary, Heron, Dwight E., additional, Collins, Sean P., additional, and Katz, Alan J., additional

Full Text
View/download PDF

43. 3D Conformal Brachytherapy for Inoperable Endometrial Carcinoma: Discrepancies between CTV EQD2 Values and Local Control

Author

Gill, Beant S., primary, Kim, Hayeon, additional, Houser, Christopher J., additional, Olsen, Adam, additional, Kelley, Joseph L., additional, Sukumvanich, Paniti, additional, Edwards, Robert P., additional, Comerci, John, additional, Olawaiye, Alexander, additional, Huang, Marilyn, additional, Courtney-Brooks, Madeleine, additional, and Beriwal, Sushil, additional

Published
2014
Full Text
View/download PDF

44. Extended Clinical Outcomes of 3D High-Dose-Rate Intracavitary Brachytherapy with MRI-Based Planning for Treatment of Cervical Cancer

Author

Gill, Beant S., primary, Kim, Hayeon, additional, Houser, Christopher J., additional, Kelley, Joseph L., additional, Sukumvanich, Paniti, additional, Edwards, Robert P., additional, Comerci, John, additional, Olawaiye, Alexander, additional, Huang, Marilyn, additional, Courtney-Brooks, Madeleine, additional, and Beriwal, Sushil, additional

Published
2014
Full Text
View/download PDF

45. Utilization and Role of Adjuvant Radiotherapy and Chemotherapy for Uterine Clear Cell Carcinoma.

Author

Karen M. Xu, Gill, Beant S., Balasubramani, Goundappa K., Sukumvanich, Paniti, Kelley, Joseph L., and Beriwal, Sushil

Abstract

Objective: Because of the rarity of uterine clear cell carcinoma (UCCC), a National Cancer Data Base analysis was conducted to evaluate practice patterns and implications of adjuvant therapy. Methods: The National Cancer Data Base was queried for UCCC patients diagnosed from 1998 to 2011. Patients receiving neoadjuvant therapy, lacking surgical staging, or having follow-up time shorter than 6 months were excluded. Factors associated with utilization were assessed using logistic regression. To define the probability of receiving chemotherapy and radiotherapy (CT + RT), propensity scores with inverse probability of treatment weighting (IPTW) were calculated using multivariable logistic regression. Log-rank test and multivariable IPTW-adjusted Cox proportional hazards modeling were then conducted. Results: A total of 2504 patients were identified, with a median follow-up of 65.5 months. Most patients had FIGO (International Federation of Gynecology and Obstetrics) stage I to II UCCC (71.4%). Adjuvant RTalone, CT alone, or CT + RTwas given in 35.3%, 9.5%, and 11.7%, respectively. Among those receiving RT, external beam was the most common modality (69.4%). Later year of diagnosis (92005: odds ratio [OR], 4.42; 95% confidence interval [95% CI], 2.44-8.01), higher FIGO stage (IIIA-IIIC2: OR, 6.34; 95% CI, 3.93-10.24), larger tumor size (3.6-5.0 cm: OR, 3.40; 95% CI, 1.76-6.55), and lymph node dissection (OR, 4.22; 95% CI, 1.60-11.15) were associated with a higher chance of receiving CT + RT. With IPTW-adjusted multivariable analysis, CT + RT significantly decreased mortality risk in stage III to IVA patients (hazards ratio, 0.41; 95% CI, 0.22-0.77), trending toward benefit in stage I to II patients (hazards ratio, 0.53; 95% CI, 0.27-1.07). Conclusions: In this hospital-based registry analysis of UCCC, adjuvant CT + RT significantly reduced the risk of death, reaching statistical significance for stage III to IVA patients. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

46. Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approach

Author

Gill, Beant, primary, Oermann, Eric, additional, Ju, Andrew, additional, Suy, Simeng, additional, Yu, Xia, additional, Rabin, Jennifer, additional, Kalhorn, Christopher, additional, Nair, Mani N., additional, Voyadzis, Jean-Marc, additional, Unger, Keith, additional, Collins, Sean P., additional, Harter, K. W., additional, and Collins, Brian T., additional

Published
2012
Full Text
View/download PDF

48. Salvage stereotactic body radiotherapy for locally recurrent non-small cell lung cancer after sublobar resection and I125 vicryl mesh brachytherapy.

Author

Gill, Beant S., Clump, David A., Burton, Steven A., Christie, Neil A., Schuchert, Matthew J., and Heron, Dwight E.

Subjects
RADIOTHERAPY, NON-small-cell lung carcinoma, RADIOISOTOPE brachytherapy, RETROSPECTIVE studies, METASTASIS, CATHETER ablation
Abstract

Purpose: Locally recurrent non-small cell lung cancer (LR-NSCLC) remains challenging to treat, particularly in patients having received prior radiotherapy. Heterogeneous populations and varied treatment intent in existing literature result in significant limitations in evaluating efficacy of lung re-irradiation. In order to better establish the impact of re-irradiation in patients with LR-NSCLC following high-dose radiotherapy, we report outcomes for patients treated with prior sublobar resection and brachytherapy that subsequently underwent stereotactic body radiotherapy (SBRT). Methods: A retrospective review of patients initially treated with sublobar resection and I125 vicryl mesh brachytherapy, who later developed LR-NSCLC along the suture line, was performed. Patients received salvage SBRT with curative intent. Dose and fractionation were based on tumor location and size, with a median prescription dose of 48 Gy in 4 fractions (range 20'60 Gy in 1'4 fractions). Results: Thirteen consecutive patients were identified with median follow-up of 2.1 years (range 0.7'5.6 years). Two in-field local failures occurred at 7.5 and 11.1 months, resulting in 2-year local control of 83.9% (95% CI, 63.5'100.0%). Two-year disease-free survival and overall survival estimates were 38.5% (95% CI, 0.0'65.0%) and 65.8% (95% CI, 38.2'93.4%). Four patients (31%) remained disease-free at last follow-up. All but one patient who experienced disease recurrence developed isolated or synchronous distant metastases. Only one patient (7.7%) developed grade ≤3 toxicity, consisting of grade 3 esophageal stricture following a centrally located recurrence previously treated with radiofrequency ablation. Conclusion: Despite high-local radiation doses delivered to lung parenchyma previously with I125 brachytherapy, re-irradiation with SBRT for LR-NSCLC results in excellent local control with limited morbidity, allowing for potential disease cure in a subset of patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results